These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 21152452)

  • 41. What lessons can be learned from failed Alzheimer's disease trials?
    Toyn J
    Expert Rev Clin Pharmacol; 2015 May; 8(3):267-9. PubMed ID: 25860157
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Eric Karran.
    Karran E; Mullard A
    Nat Rev Drug Discov; 2015 Apr; 14(4):230-1. PubMed ID: 25792262
    [No Abstract]   [Full Text] [Related]  

  • 43. A map of Alzheimer's disease-signaling pathways: a hope for drug target discovery.
    Ogishima S; Mizuno S; Kikuchi M; Miyashita A; Kuwano R; Tanaka H; Nakaya J
    Clin Pharmacol Ther; 2013 May; 93(5):399-401. PubMed ID: 23511713
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Challenges, solutions, and recommendations for Alzheimer's disease combination therapy.
    Hendrix JA; Bateman RJ; Brashear HR; Duggan C; Carrillo MC; Bain LJ; DeMattos R; Katz RG; Ostrowitzki S; Siemers E; Sperling R; Vitolo OV
    Alzheimers Dement; 2016 May; 12(5):623-30. PubMed ID: 27017906
    [TBL] [Abstract][Full Text] [Related]  

  • 45. American Chemical Society--233rd National Meeting. Protein fragment screening in novel drug design. 25-29 March 2007, Chicago, IL, USA.
    Bright J
    IDrugs; 2007 May; 10(5):308-9. PubMed ID: 17487779
    [No Abstract]   [Full Text] [Related]  

  • 46. Conformational restriction: an effective tactic in 'follow-on'-based drug discovery.
    Fang Z; Song Y; Zhan P; Zhang Q; Liu X
    Future Med Chem; 2014 May; 6(8):885-901. PubMed ID: 24962281
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Current treatment and recent clinical research in Alzheimer's disease.
    Neugroschl J; Sano M
    Mt Sinai J Med; 2010; 77(1):3-16. PubMed ID: 20101716
    [TBL] [Abstract][Full Text] [Related]  

  • 48. An Ethical Argument for Ending Human Trials of Amyloid-Lowering Therapies in Alzheimer's Disease.
    Daly T; Herrup K; Espay AJ
    AJOB Neurosci; 2024; 15(2):80-81. PubMed ID: 36197130
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Drug repositioning for Alzheimer's disease.
    Corbett A; Pickett J; Burns A; Corcoran J; Dunnett SB; Edison P; Hagan JJ; Holmes C; Jones E; Katona C; Kearns I; Kehoe P; Mudher A; Passmore A; Shepherd N; Walsh F; Ballard C
    Nat Rev Drug Discov; 2012 Nov; 11(11):833-46. PubMed ID: 23123941
    [TBL] [Abstract][Full Text] [Related]  

  • 50. 12th International Conference on Alzheimer's Disease (ICAD), Vienna, Austria.
    Strobel G
    J Alzheimers Dis; 2009; 18(4):973-90. PubMed ID: 20009238
    [No Abstract]   [Full Text] [Related]  

  • 51. Drug discovery, development and delivery in Alzheimer's disease.
    Brambilla D
    Pharm Res; 2017 Dec; 35(1):3. PubMed ID: 29288429
    [No Abstract]   [Full Text] [Related]  

  • 52. Therapeutic potential of nanoemulsions as feasible wagons for targeting Alzheimer's disease.
    Handa M; Tiwari S; Yadav AK; Almalki WH; Alghamdi S; Alharbi KS; Shukla R; Beg S
    Drug Discov Today; 2021 Dec; 26(12):2881-2888. PubMed ID: 34332094
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Many are called, yet few are chosen. Are neuropsychiatric clinical trials letting us down?
    McArthur R
    Drug Discov Today; 2011 Mar; 16(5-6):173-5. PubMed ID: 21163366
    [No Abstract]   [Full Text] [Related]  

  • 54. On weighted composite scores for early Alzheimer's trials.
    Jin K; Cameron B; Dunn B
    Pharm Stat; 2019 Mar; 18(2):239-247. PubMed ID: 30565432
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Amyloid Cascade Hypothesis for the Treatment of Alzheimer's Disease: Progress and Challenges.
    Wu T; Lin D; Cheng Y; Jiang S; Riaz MW; Fu N; Mou C; Ye M; Zheng Y
    Aging Dis; 2022 Dec; 13(6):1745-1758. PubMed ID: 36465173
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Alzheimer's disease drug development in 2008 and beyond: problems and opportunities.
    Becker RE; Greig NH
    Curr Alzheimer Res; 2008 Aug; 5(4):346-57. PubMed ID: 18690832
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Translation of Pre-Clinical Studies into Successful Clinical Trials for Alzheimer's Disease: What are the Roadblocks and How Can They Be Overcome?
    Banik A; Brown RE; Bamburg J; Lahiri DK; Khurana D; Friedland RP; Chen W; Ding Y; Mudher A; Padjen AL; Mukaetova-Ladinska E; Ihara M; Srivastava S; Padma Srivastava MV; Masters CL; Kalaria RN; Anand A
    J Alzheimers Dis; 2015; 47(4):815-43. PubMed ID: 26401762
    [TBL] [Abstract][Full Text] [Related]  

  • 58. How efficient are rodent models for Alzheimer's disease drug discovery?
    Guo B; Zhou Q
    Expert Opin Drug Discov; 2018 Feb; 13(2):113-115. PubMed ID: 29082769
    [No Abstract]   [Full Text] [Related]  

  • 59. Alzheimer's disease market: hope deferred.
    Gerald Z; Ockert W
    Nat Rev Drug Discov; 2013 Jan; 12(1):19-20. PubMed ID: 23274463
    [No Abstract]   [Full Text] [Related]  

  • 60. Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer's disease.
    Aisen PS; Vellas B; Hampel H
    Nat Rev Drug Discov; 2013 Apr; 12(4):324. PubMed ID: 23493086
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.